Generare

Generare is pioneering a new paradigm in drug discovery by systematically accessing the estimated 97% of microbial chemistry that has never been expressed or screened. The company's integrated platform combines microbiology, analytics, and data science to extract, purify, identify, and annotate novel natural molecules at industrial scale, creating a unique and proprietary dataset. Each discovered molecule enriches its predictive algorithms, creating a compounding data advantage aimed at delivering high-quality drug candidates, particularly in areas of high unmet need like antimicrobial resistance. Based in Paris, Generare is a private, pre-revenue platform company building a foundational asset in bioactive natural product discovery.

Integrated platform that unearths, decodes, and compounds novel small molecules from untapped microbial biodiversity. It combines advanced microbiology, analytics, and data science to create a proprietary dataset of evolution-derived chemistry, using a self-improving feedback loop to accelerate discovery.

Generare competes with other biotechs using genomics and metagenomics to mine microbial biodiversity for drug discovery (e.g., Hexagon Bio, Lodo Therapeutics). Its differentiation claims are an industrial-scale, integrated wet-lab/dry-lab platform and a focus on generating a proprietary data feedback loop from molecules never seen before by AI.